Luminex Corporation Places 5,000th Instrument

  
    
  
  
    
      Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed 
      solutions, today announced that it has recently delivered its 5,000th 
      instrument to Beaumont Hospital in Royal Oak, Michigan. Beaumont 
      Hospital, Royal Oak, will use the Luminex® 200™ 
      instrument to perform the FDA-cleared Luminex xTAG™ 
      Respiratory Viral Panel (RVP) to assist doctors in diagnosing 
      respiratory infections quickly.
    
    
      “Multiplexing is, in many ways, the future of 
      molecular diagnostics," said Dr. Domnita Crisan, medical director of the 
      molecular pathology laboratory at Beaumont Hospital, Royal Oak. “The 
      ability to run many tests at once provides us faster, more clinically 
      relevant results. The Luminex instrument is an important multiplexing 
      tool for us. It provides accurate results very quickly and efficiently, 
      and is easy to use.”
    
    
      The Luminex analyzer is a unique instrument that can be used across the 
      continuum of science and healthcare – from 
      basic research to clinical diagnostics. The instrument can be found in 
      pharmaceutical and academic research laboratories, clinical reference 
      laboratories and hospitals of all sizes.
    
    
      “Delivering our 5,000th 
      instrument is an important milestone for Luminex as our proprietary xMAP® 
      Technology, driven by the test menu expansion of our partners and the 
      Luminex Assay Group, continues to gain momentum in the marketplace,” 
      said Patrick J. Balthrop, president and chief executive officer of 
      Luminex Corporation. “Our product portfolio 
      now includes a diversity of applications, such as the newly launched 
      xTAG RVP and FlexmiR™ microRNA assays. These 
      tests, combined with our partners’ 
      developments in protein research, immunodiagnostics, HLA and other 
      areas, have led to record instrument sales for Luminex. We look forward 
      to working with our partners and end-users to continue finding new ways 
      our xMAP Technology can advance science and healthcare.”
    
    
      Luminex instruments are flexible analyzers based on the principles of 
      three-dimensional bead arrays. Due to the enhanced liquid kinetics of 
      the microspheres in solution, these arrays offer superior uniformity and 
      faster reaction times than standard two-dimensional planar arrays. 
      Proprietary xMAP Technology from Luminex also provides the laboratory 
      the power of multiplexing and the ability to produce superior results in 
      much less time than traditional methods like ELISA or real-time PCR. 
      Luminex develops and manufactures state-of-the-art assay products, and 
      licenses its instruments and bead-based xMAP technology to 
      market-leading companies in clinical diagnostics and biological 
      research. Assays from Luminex and its partners deliver fast and 
      cost-effective results for nucleic acid assays, receptor-ligand assays, 
      immunoassays and enzymatic assays.
    
    
      About Luminex Corporation
    
    
      Luminex Corporation develops, manufactures and markets proprietary 
      biological testing technologies with applications throughout the 
      diagnostic and life sciences industries. The Company's xMAP® 
      multiplex solutions include an open-architecture, multi-analyte 
      technology platform that delivers fast, accurate and cost-effective 
      bioassay results to markets as diverse as pharmaceutical drug discovery, 
      clinical diagnostics and biomedical research, including the genomics and 
      proteomics research markets. The Company's xMAP technology is sold 
      worldwide and is already in use in leading clinical laboratories as well 
      as major pharmaceutical, diagnostic and biotechnology companies. Further 
      information on Luminex Corporation or xMAP technology can be obtained at www.luminexcorp.com.